drug
Postinor
Marketedupdated 3mo agoby Foundation Consumer Healthcare LLC
Approvedcommunity read0 votes
all catalysts(1)
Trials studying Postinor
- phase1A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants
- phase3Efficacy, Safety, and Tolerability of Levonorgestrel Vaginal System
- phase1Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
- phase1A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity
- phase1A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives
- phase1A Study of Elenestinib in Healthy Adult Female Participants
- phase1Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)
- phase1A Research Study Looking Into the Effect of NNC0519-0130 on Blood Levels of a Birth Control Pill and Emptying of the Stomach in Women After Menopause
Patent cliff
source: FDA Orange Bookfirst barrier falls
Feb 7, 2027
176 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (12)
- Sep 7, 2040formulationUS 11571328
- Mar 22, 2034formulationUS 10028858
- Oct 24, 2033method-of-use (U-2348)US 11090186
- Oct 6, 2033compositionUS 12004992
- Sep 16, 2029method-of-use (U-2948)US 105615243.1y
- Sep 16, 2029method-of-use (U-2948)US 105615243.1y
- Sep 16, 2029method-of-use (U-2948)US 105615243.1y
- Sep 14, 2029formulationUS 118501823.1y
- Sep 14, 2029formulationUS 118501823.1y
- Sep 14, 2029formulationUS 118501823.1y
- Feb 7, 2027formulationUS 11628088176d
- Feb 7, 2027formulationUS 11628088176d
FDA exclusivities (1)
- Jun 29, 2026I-917Indication (3y)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 10m ago
Found something off?
comments(0)
5-min edit window · permanent after that